Phocas Financial Corp. Decreases Stock Position in Elanco Animal Health Incorporated $ELAN

Phocas Financial Corp. decreased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 16.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 182,755 shares of the company’s stock after selling 37,204 shares during the period. Phocas Financial Corp.’s holdings in Elanco Animal Health were worth $4,136,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Elanco Animal Health during the 1st quarter valued at approximately $2,065,000. Goldman Sachs Group Inc. raised its holdings in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after acquiring an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after purchasing an additional 76,408 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Elanco Animal Health by 59.9% in the second quarter. American Century Companies Inc. now owns 203,567 shares of the company’s stock valued at $2,907,000 after purchasing an additional 76,230 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Stock Up 0.1%

Shares of NYSE ELAN opened at $23.11 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. The stock has a 50 day moving average price of $24.56 and a 200 day moving average price of $22.85. The firm has a market capitalization of $11.49 billion, a price-to-earnings ratio of -48.14, a PEG ratio of 2.94 and a beta of 1.88. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $27.72.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the firm posted $0.14 EPS. The company’s revenue for the quarter was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ELAN. KeyCorp upped their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Friday, March 27th. Leerink Partners raised their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. Finally, Morgan Stanley raised their price target on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.67.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.